The aim is to understand how high-density lipoprotein (HDL) function can be effectively translated into clinical practice to mitigate cardiovascular risk.
Randomized trial conducted in patients at risk for cardiovascular disease.
Assessment of HDL function using specific biomarkers.
Implementation of clinical guidelines based on findings.
Improved HDL function correlated with a 30% reduction in cardiovascular events (HR 0.70, 95% CI 0.55-0.89, p=0.004).
Clinical guidelines led to a significant increase in appropriate HDL screening and management.
HDL-related biomarkers showed predictive value for cardiovascular outcomes.